Medtronic plc (MDT)
| Market Cap | 109.54B |
| Revenue (ttm) | 31.96B |
| Net Income (ttm) | 4.10B |
| Shares Out | 1.33B |
| EPS (ttm) | 3.07 |
| PE Ratio | 26.83 |
| Forward PE | 15.81 |
| Dividend | $2.76 (3.35%) |
| Ex-Dividend Date | Dec 19, 2023 |
| Volume | 2,882,474 |
| Open | 82.53 |
| Previous Close | 82.73 |
| Day's Range | 82.14 - 82.90 |
| 52-Week Range | 68.84 - 92.02 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 94.92 (+15.22%) |
| Earnings Date | Feb 20, 2024 |
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accesso... [Read more]
Financial Performance
In 2023, Medtronic's revenue was $31.23 billion, a decrease of -1.45% compared to the previous year's $31.69 billion. Earnings were $3.76 billion, a decrease of -25.42%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for MDT stock is "Buy." The 12-month stock price forecast is $94.92, which is an increase of 15.22% from the latest price.
News
Final Trade: ETH, BABA, MDT, ET
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference
DUBLIN , Dec. 18, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 42nd annual J.P. Morgan healthcare conference on M...
Medtronic gets FDA approval for new heart-condition treatment
Medtronic said the U.S. Food and Drug Administration has approved its PulseSelect Pulsed Field Ablation System for the treatment of two heart conditions.
US FDA approves Medtronic's system for heart condition
Medtronic said on Wednesday that the U.S. Food and Drug Administration (FDA) had approved its system for a type of condition that can cause stroke or heart failure.
Medtronic creates history with FDA approval of its novel PulseSelect™ Pulsed Field Ablation System to treat atrial fibrillation
Safe, efficient, and effective treatment for both paroxysmal and persistent atrial fibrillation DUBLIN , Dec. 13, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technolo...
3 of the Best Stocks for Value Investors to Buy Now
#Morningstar #ComcastStock #StockInvesting These cheap stocks from companies with wide economic moats look attractive for 2024. 00:00 Introduction 00:46 Medtronic MDT 01:21 Comcast CMCSA 02:00 RTX RT...
Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care
Agreement Expands Partnership Between Cosmo Pharmaceuticals and Medtronic, Set to Transform Endoscopy with Cutting-Edge AI Technology Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsf...
Medtronic and Cosmo Pharmaceuticals forge ahead in AI-driven care
Agreement expands partnership between Medtronic and Cosmo Pharmaceuticals, set to transform endoscopy with cutting-edge AI technology DUBLIN , Dec. 11, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), ...
Medtronic announces cash dividend for third quarter of fiscal year 2024
DUBLIN , Dec. 7, 2023 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 7, 2023, approved the company's cash dividend for the third quarter of fiscal year 2024 o...
Should You Pick Medtronic Stock At $80 After An Upbeat Q2?
Medtronic (NYSE: MDT) recently reported its Q2 fiscal 2024 results (fiscal ends in April), with revenues and earnings beating our estimates, and we believe that MDT st
Medtronic: oversold, overextended high yield reversal in play
After two years of correction and downtrend, providing ample incentive to buyers all along the way, medical device maker Medtronic NYSE: MDT has finally reached its bottom, and the reversal is on. The...
The impact of wight-loss drugs to our business 'is negligable', says Medtronic CEO
Geoff Martha, Medtronic CEO, joins 'Closing Bell Overtime' to talk quarterly results, the impact of weight-loss drugs, and more.
Medtronic's second-quarter earnings top estimates as medical device maker raises guidance
Medtronic PLC's stock MDT rose 0.8% premarket Tuesday, after the medical device maker posted better-than-expected earnings for its fiscal second quarter and raised guidance. Dublin-based Medtronic pos...
Medical device maker Medtronic raises fiscal 2024 profit view
Medtronic on Tuesday raised its annual profit forecast for the second time this year, banking on higher demand for its medical devices as surgery volumes pick up pace.
Medtronic reports second quarter fiscal 2024 financial results
Solid execution results in mid-single digit revenue growth, driven by broad-based strength across multiple businesses and geographies; Major innovative product approvals; Raises fiscal year guidance D...
Earnings Exchange: Medtronic, Agilent Technologies & Trip.com
Ari Wald, managing director and head of technical analysis at Oppenheimer, joins 'The Exchange' to discuss Medtronic, Agilent Technologies, and Trip.com.
After A 6% Rise This Month Should You Pick Medtronic Stock Ahead Of Its Q2?
We expect Medtronic stock to trade sideways post-Q2 results announcement, with its revenues and earnings expected to miss the street estimates marginally.
US FDA approves Medtronic's blood pressure treatment device for use
The U.S. Food and Drug Administration on Friday approved the use of Medtronic's treatment device in a surgery called renal denervation in patients whose high blood pressure cannot be controlled by dru...
Medtronic announces FDA approval of minimally invasive device to treat hypertension
The Symplicity ™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure Approval is the culmination of ten years of clinical research and development of the Medtron...
A majority of Americans are optimistic that AI will improve healthcare in 2024
According to a new survey from Medtronic and Morning Consult, respondents recognize potential of AI to enable earlier diagnosis and improve access to care DUBLIN , Nov. 13, 2023 /PRNewswire/ -- More t...
Three value stock picks from a veteran manager with a good performance record
For many years through 2022, it was becoming more difficult for active fund managers to make the case for their services, when broad index funds, with lower fees, were performing so well. But the tech...
Medtronic to announce financial results for its second quarter of fiscal year 2024
DUBLIN , Nov. 7, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2...
Medtronic Evolut™ TAVR platform outperforms surgery with sustained valve performance for low-risk patients at four years
TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk Trial DUBLIN and SAN FRANCISCO , Oct. 24, 2023 /PRNewswire/ -- Medtroni...